Tuesday, June 16, 2026

Hunger Strike Ends in Hospitalization: What Jang Dong-hyuk’s Collapse Signals for South Korea’s Political Standoff

Jang Dong Hyuk, leader of the People Power Party, hospitalized after hunger strike; doctors prioritize cardiac tests amid health concerns.

Trump Hits Canada With 35% Tariffs—Why Ottawa Is Now Cutting EV Deals With China

Canada seeks improved ties with China, reducing tariffs on electric vehicles, amid strained US-Canada relations since Trump's tariffs.

North Korea Claims New Missile Launchers Ready: What Does It Mean for Us?

North Korea's claim that they have deployed 250 new tactical ballistic missile launchers to the front line.

Tag: clinical trials

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

ABL209: The Promising Dual Antibody ADC Revolutionizing Cancer Treatment in 2026

ABL Bio's ABL209 shows promising anti-cancer effects with broad safety in preclinical studies, advancing to Phase 1 trials in the U.S.

Revolutionary Long-Lasting Injections: How IVL3003 and IVL3004 are Transforming Dementia and Addiction Treatments

Inventage Lab will present promising results from clinical trials of two long-acting injectables at the 2026 AAN meeting in Chicago.

CGBio’s DCLASSY PDRN receives clinical trial approval from MFDS

CGBio's DCLASSY PDRN skin booster gains IDE approval for clinical trials targeting eye wrinkles, enhancing patient satisfaction and market competitiveness.

Fexuclue 40mg: How This New GERD Treatment is Revolutionizing Healthcare in Indonesia

Daewoong Pharmaceutical's Fexuclue receives approval in Indonesia for treating GERD, aiming for rapid expansion in the market.

Next-Gen Cancer Drug Nesuparib: How It Outperforms Olaparib in SCLC and Pancreatic Cancer

Onconic Therapeutics will present Nesuparib research at AACR 2026, showcasing its potential for various cancers and overcoming PARP inhibitor limitations.

Samsung Bioepis Launches SBE303: The First ADC Drug Candidate Targeting Nectin-4 in Cancer Trials

Samsung Bioepis has begun Phase 1 trials for its ADC candidate SBE303, targeting solid tumors, set to continue until July 2030.

YH35995: A Game-Changer for Gaucher Disease? FDA Grants Orphan Drug Designation

Yuhan Corp's YH35995 for Gaucher disease receives orphan drug designation, enhancing its development for rare diseases with unmet needs.

Imeroprubart vs. Batoclimab: Which Treatment Will Revolutionize Graves’ Disease Management?

HanAll Biopharma's Imeroprubart targets Graves' disease, showing promise with IgG suppression and user-friendly auto-injector delivery.

JW Pharmaceuticals Secures Exclusive Rights for Innovative GLP-1 Drug Vopaglutide in South Korea

JW Pharmaceutical secures exclusive rights for Vopaglutide, a promising treatment for diabetes and obesity, with significant milestone payments.

GI-101A: Breakthrough Immuno-Oncology Drug Set for ASCO 2026 Presentation

GI Innovation's GI-101A will be presented at ASCO 2026, highlighting its clinical potential and significance in oncology.

Is A Breakthrough For Thyroid Eye Disease Still Out Of Reach?

HanAll Biopharma's Phase 3 trial of batoclimab for Thyroid Eye Disease failed to show statistical significance, but safety profiles remain consistent.

JW Pharmaceutical Secures Phase 1 Approval for Novel Hair Loss Treatment JW0061—What to Expect?

JW Pharmaceutical is investing in innovative hair loss treatments and expanding its drug portfolio, including successful cholesterol medications.

Alpha Tau Medical’s Alpha DaRT: A New Hope for Pancreatic Cancer Patients – What You Need to Know

Alpha Tau Medical will present clinical results of its DaRT technology for pancreatic cancer at DDW 2026, marking a significant milestone.

How AI Read CXR is Transforming Chest X-Ray Analysis: A Deep Dive into the First AI Medical Device Approved in Korea

South Korea's first generative AI medical device, AI Read X-ray, gains approval for interpreting X-rays with radiologist-level accuracy.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.